Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.

Helland F, Hallin Henriksen M, Gerke O, Vogsen M, Høilund-Carlsen PF, Hildebrandt MG.

Diagnostics (Basel). 2019 Aug 27;9(3). pii: E106. doi: 10.3390/diagnostics9030106. Review.

2.

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond.

Hildebrandt MG, Lauridsen JF, Vogsen M, Holm J, Vilstrup MH, Braad PE, Gerke O, Thomassen M, Ewertz M, Høilund-Carlsen PF; Centre for Personalized Response Monitoring in Oncology (PREMIO).

Cancers (Basel). 2019 Aug 15;11(8). pii: E1190. doi: 10.3390/cancers11081190.

3.

Hybrid PET/MRI in major cancers: a scoping review.

Morsing A, Hildebrandt MG, Vilstrup MH, Wallenius SE, Gerke O, Petersen H, Johansen A, Andersen TL, Høilund-Carlsen PF.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2138-2151. doi: 10.1007/s00259-019-04402-8. Epub 2019 Jul 2.

PMID:
31267161
4.

Stewart-Treves Syndrome on the Lower Extremity Associated to Idiopathic Chronic Lymphedema Visualized on FDG PET/CT.

Brittain JM, Nymark T, Hildebrandt MG, Hovgaard D, Andersen KF.

Clin Nucl Med. 2017 Dec;42(12):e519-e522. doi: 10.1097/RLU.0000000000001856.

PMID:
29035997
5.

Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study.

Gerke O, Vilstrup MH, Halekoh U, Hildebrandt MG, Høilund-Carlsen PF.

EJNMMI Res. 2017 Sep 26;7(1):79. doi: 10.1186/s13550-017-0328-6.

6.

[18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.

Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, Petersen H, Larsen LB, Duvnjak S, Buskevica I, Bektas S, Søe K, Jylling AM, Ewertz M, Alavi A, Høilund-Carlsen PF.

J Clin Oncol. 2016 Jun 1;34(16):1889-97. doi: 10.1200/JCO.2015.63.5185. Epub 2016 Mar 21.

PMID:
27001573
7.

[¹⁸F]fluorodeoxyglucose PET/computed tomography in breast cancer and gynecologic cancers: a literature review.

Hildebrandt MG, Kodahl AR, Teilmann-Jørgensen D, Mogensen O, Jensen PT.

PET Clin. 2015 Jan;10(1):89-104. doi: 10.1016/j.cpet.2014.09.007. Epub 2014 Nov 22. Review.

PMID:
25455882
8.

Utility of 18FDG-PET/CT in breast cancer diagnostics--a systematic review.

Warning K, Hildebrandt MG, Kristensen B, Ewertz M.

Dan Med Bull. 2011 Jul;58(7):A4289. Review.

PMID:
21722539
9.

Low risk of recurrence in breast cancer with negative sentinel node.

Hildebrandt MG, Bartram P, Bak M, Højlund-Carlsen M, Petersen H, Grupe P, Knoop A, Ryttov N, Højlund-Carlsen PF.

Dan Med Bull. 2011 Apr;58(4):A4255.

PMID:
21466764
10.

Gender differences in severity, symptomatology and distribution of melancholia in major depression.

Hildebrandt MG, Stage KB, Kragh-Soerensen P; Danish University Antidepressant Group.

Psychopathology. 2003 Jul-Aug;36(4):204-12.

PMID:
14504455
11.

Are gender differences important for the clinical effects of antidepressants?

Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P; Danish University Antidepressant Group.

Am J Psychiatry. 2003 Sep;160(9):1643-50.

PMID:
12944340

Supplemental Content

Loading ...
Support Center